Biogen International GmbH, Neuhofstrasse 30, 6340 Baar, Switzerland.
Pall Corporation World Headquarters, 25 Harbor Park Drive, Port Washington, NY 11050.
PDA J Pharm Sci Technol. 2020 Sep-Oct;74(5):524-562. doi: 10.5731/pdajpst.2019.011387. Epub 2020 May 28.
Eudralex volume 4, Annex 1, the European Union Good Manufacturing Practice for sterile products, requires that "The integrity of the sterilised filter should be verified before use" (1). Implicit in this requirement for a PUPSIT is the rationale that the sterilizing filter could sustain damage during sterilization or use (i.e., subsequent to any pre-use test conducted prior to sterilization), causing a defect which would not be detected by the post-use integrity ("masked" during filtration). To assess whether a filter defect could be masked by partial filter plugging, we evaluated the impact of the bacterial challenge test (BCT) on the bubble point (BP) of the test filters. The BP tests that are conducted before and after the BCT have been collected and compared for 2086 filters (1571 × test filters and 515 × control filters), representing 531 BCTs on 518 different pharmaceutical products, buffers, and in-process fluids. These tests comprise a cross section of fluids from multiple firms spanning the pharmaceutical and biotechnology industry. A posttest to pretest BP ratio was calculated for each filter and the distribution of these ratios examined to determine whether there were cases of elevation of the BP because of bacterial loading to the point where masking of a filter defect could occur; that is, if a defective filter could pass integrity testing due to apparent reduction in filter pore size because of the bacteria retained during the BCT. Ratios were averaged across all tests for the same test fluid. The mean average ratio was 1.00 ± 0.15, indicating that on the average, elevation of the BP does not occur. To assess the risk of masking a filter defect, observed BP ratios were compared to the ratio of the minimum BP specification of a 0.2 μm filter to that of a 0.45 μm filter of the same membrane type. The lowest such ratio for any membrane type was 1.33. A BP ratio equal to or higher than this ratio was considered a risk for masking, because a 0.45 μm filter could appear to meet the specifications of a 0.2 μm filter. Out of 518 average BP ratios, only eight fluids (1.5%) produced BP ratios meeting this criterion for a masking risk. Potential risk factors associated with these cases are discussed. We conclude that filtration processes producing BP changes sufficient to present a risk of masking defects are not common, and are detectable during the routine BCT. The BP ratios observed during routine BCT are one means to assess the potential of a given filtration process to mask defects and can be considered when determining whether a PUPSIT should be implemented.
Eudralex 卷 4,附录 1,欧盟无菌产品良好生产规范要求“在使用前应验证已灭菌过滤器的完整性”(1)。这就需要进行 PUPSIT,其基本原理是灭菌过滤器在灭菌或使用过程中(即在灭菌前进行的任何使用前测试之后)可能会受到损坏,从而导致在使用后完整性测试中不会发现的缺陷(在过滤过程中“被掩盖”)。为了评估过滤器缺陷是否可能因部分过滤器堵塞而被掩盖,我们评估了细菌挑战测试(BCT)对测试过滤器的起泡点(BP)的影响。在进行 BCT 之前和之后收集并比较了 2086 个过滤器(1571 个测试过滤器和 515 个对照过滤器)的 BP 测试结果,这些测试结果代表了 518 种不同药品、缓冲液和中间流体的 531 个 BCT。这些测试涵盖了来自多个公司的多种流体,涉及制药和生物技术行业。为每个过滤器计算了测试后与测试前 BP 的比值,并检查了这些比值的分布,以确定是否存在因细菌负荷而导致 BP 升高的情况,即如果因 BCT 期间截留的细菌而导致过滤器缺陷的孔径明显减小,那么有缺陷的过滤器是否可以通过完整性测试。对于同一测试流体,所有测试的平均值都进行了平均。平均比值为 1.00±0.15,表明平均而言,BP 升高的情况并未发生。为了评估掩盖过滤器缺陷的风险,将观察到的 BP 比值与相同膜类型的 0.2μm 过滤器的最小 BP 规格与 0.45μm 过滤器的比值进行了比较。任何膜类型的最低比值为 1.33。等于或高于该比值的 BP 比值被认为是掩盖的风险,因为 0.45μm 过滤器可能看起来符合 0.2μm 过滤器的规格。在 518 个平均 BP 比值中,只有 8 种流体(1.5%)的 BP 比值达到了掩盖风险的标准。讨论了与这些情况相关的潜在风险因素。我们得出结论,产生足以导致缺陷掩盖风险的 BP 变化的过滤过程并不常见,并且在常规 BCT 期间可以检测到。在常规 BCT 期间观察到的 BP 比值是评估特定过滤过程掩盖缺陷潜力的一种手段,在确定是否应实施 PUPSIT 时可以考虑。